BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched.

“Everything Visible” is a practical tool book that systematically introduces how data visualization can be applied to clinical clinical research. It is co-written and reviewed by senior forces in the medical, research, academic, and enterprise industries, and published by the Science and Technology Literature Press to provide a reference for the digital transformation of clinical research in China. Starting from the top ten clinical application scenarios of medicine, the book covers the entire drug life cycle from early R&D and clinical trials to real-world research after marketing, and provides theoretical explanations and practical case sharing in multiple dimensions such as visualization requirements, technical status and accessibility, visual application scenarios, and general principles to help clinicians more quickly and accurately identify data values and trends, thereby contributing to clinical trial strategy formulation and review of efficacy results.

Dr. Wu Xiaobin, President and Chief Operating Officer of BeiGene, said, “I am very happy to see another clinical research tool written with the participation of BeiGene. As an innovative oncology treatment company with a global layout in the entire R&D, production and commercialization industry chain, we are always thinking about how to use the company's unique advantages to support the development of the pharmaceutical industry. We hope that this toolbook, which uses data visualization as an entry point, will help doctors and researchers improve clinical research efficiency, promote cutting-edge communication, create high-quality scientific research results, and better meet the unmet needs of cancer patients.”

Dr. Wang Tongyan, senior vice president of DIA Global and managing director in China, said, “The publication of “Everything Is Visible” was a breakthrough attempt to gather industry wisdom, show the achievements of the industry, and feed back the transformation and development of the industry. I am also very honored and surprised to witness the book from insight into needs, joint review to compilation into a book. If the pharmaceutical industry is to move towards high-quality development, it must insist on R&D and innovation. DIA and BeiGene Shenzhou coincide and work hand in hand in this regard. We will continue to work cooperatively with all sectors to advance science, research, and society, and ultimately improve treatment outcomes for patients around the world.”

In order to promote the sustainable improvement of clinical diagnosis, treatment and research standards for cancer diseases and support hospitals to achieve high-quality development, BeiGene Shenzhou relied on the company's global R&D advantages and a strong commercialization network to establish a “Baekje Star” innovation project in China in 2022, with three modules: clinical research capability training, clinical research academic exchange, and clinical research tool book development.

As an output of the “Baekje Star” clinical research toolbook development module, the first self-authored clinical research toolbook “Together” was launched in December 2023, with sales exceeding 10,000 within 3 months, reflecting the industry's urgent need to cultivate innovative medical talents and transform clinical research results. (Link to related press release)

“Everything Is Visible” can now be purchased through major book purchase channels, and “Together We Work Together” is also on sale.

About BeiGene

BeiGene is a global oncology innovation company focused on developing innovative anti-tumor drugs for cancer patients around the world. Through strong independent research and development capabilities and external strategic cooperation, we continue to accelerate the development of diverse and innovative drug pipelines and product portfolios, and are committed to comprehensively improving drug accessibility and affordability for more patients around the world. We have a team of over 10,000 people across five continents. For more information, please visit or follow the “BeiGene State” WeChat account.

About Baekje Star

In order to promote the sustainable improvement of clinical diagnosis, treatment and research standards for cancer diseases and support hospitals to achieve high-quality development, BeiGene Shenzhou has set up the “Baekje Star” innovation project to build a platform for industry empowerment and exchange for improving clinical research capabilities in China. Relying on the company's global R&D advantages and focusing on real-world clinical needs and challenges, the project has now established three major modules: clinical research capability training, clinical research academic exchange, and clinical research tool book development. The aim is to comprehensively help cultivate high-quality medical innovators, transform clinical research results, and ultimately benefit the inexhaustible needs of patients.

About the Drug Information Association (DIA) andDIAChina Digital Health Community (DHC)

Established in 1964, DIA (Drug Information Association) is a world-renowned non-profit, multi-disciplinary, member-led pharmaceutical professional association. It is a global academic platform for promoting drug innovation and pharmacy development. It enjoys a high reputation in the field of global pharmaceutical research and development. Since 2009, DIA China has continued to rely on top global regulatory and drug development resources to provide a globally neutral full-life cycle drug development academic communication platform for Chinese pharmaceutical innovation to address innovation challenges and encourage open dialogue between thought leaders and regulators.

DIA China Digital Health Community (DHC) is currently one of the top ten professional communities in DIA China. It is committed to providing an exchange platform for industry-leading technology and best practices in various fields to promote the improvement of the quality and efficiency of clinical research.

About the book “Everything Is Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development”

“Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (“Everything Visible” for short) is a practical tool book introducing how data visualization can be applied to clinical clinical research in medicine. It was prepared by BeiGene and the Drug Information Association (DIA) China Digital Health Community (DHC) organization and published by Science and Technology Literature Press to provide a reference for the digital transformation of clinical research in China. Starting from the top ten clinical application scenarios of medicine, the book covers the entire drug life cycle from early R&D and clinical trials to real-world research after marketing, and provides theoretical explanations and practical case sharing in multiple dimensions such as visualization requirements, technical status and accessibility, visual application scenarios, and general principles to help clinicians more quickly and accurately identify data values and trends, thereby contributing to clinical trial strategy formulation and review of efficacy results.

Disclaimers:“Everything Visible” provides information and knowledge sharing, and should not be regarded as any medical advice. Readers can use the content or services provided by the book for personal study, research or appreciation, and other non-commercial purposes, but they must also abide by the provisions of copyright law and other relevant laws, and must not infringe on the legal rights of the book and related rights holders.